A detailed history of Jpmorgan Chase & CO transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18,543 shares of GLUE stock, worth $157,430. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,543
Previous 13,418 38.19%
Holding current value
$157,430
Previous $50,000 96.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$3.59 - $6.97 $18,398 - $35,721
5,125 Added 38.19%
18,543 $98,000
Q2 2024

Aug 12, 2024

BUY
$3.38 - $7.86 $2,017 - $4,692
597 Added 4.66%
13,418 $50,000
Q1 2024

May 10, 2024

SELL
$4.26 - $8.46 $39,255 - $77,958
-9,215 Reduced 41.82%
12,821 $90,000
Q4 2023

Feb 12, 2024

SELL
$2.5 - $5.93 $18,545 - $43,988
-7,418 Reduced 25.19%
22,036 $124,000
Q3 2023

Nov 14, 2023

BUY
$4.78 - $7.22 $19,244 - $29,067
4,026 Added 15.83%
29,454 $141,000
Q2 2023

Aug 11, 2023

BUY
$4.53 - $8.4 $4,656 - $8,635
1,028 Added 4.21%
25,428 $174,000
Q1 2023

May 18, 2023

BUY
$5.95 - $8.21 $135,576 - $187,073
22,786 Added 1411.77%
24,400 $190,000
Q1 2023

May 11, 2023

SELL
$5.95 - $8.21 $99,495 - $137,287
-16,722 Reduced 91.2%
1,614 $12,000
Q4 2022

Feb 13, 2023

SELL
$6.71 - $9.72 $4,743 - $6,872
-707 Reduced 3.71%
18,336 $140,000
Q3 2022

Nov 14, 2022

BUY
$7.17 - $12.16 $9,571 - $16,233
1,335 Added 7.54%
19,043 $156,000
Q2 2022

Aug 11, 2022

SELL
$6.15 - $14.99 $29,544 - $72,011
-4,804 Reduced 21.34%
17,708 $171,000
Q1 2022

May 11, 2022

BUY
$10.36 - $20.41 $112,281 - $221,203
10,838 Added 92.84%
22,512 $316,000
Q4 2021

Feb 10, 2022

BUY
$16.28 - $27.15 $117,899 - $196,620
7,242 Added 163.4%
11,674 $239,000
Q3 2021

Nov 12, 2021

BUY
$18.59 - $42.21 $82,390 - $187,074
4,432 New
4,432 $99,000

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $397M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.